ArticleNature medicine2026

Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial.

Timothy A Yap et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.